Publications

  1. Rudick RA, Joynt RJ. Normal pressure hydrocephalus: A treatable dementia. Texas Medicine 1980;76:46-49.
  2. Rudick RA, Satran R, Eskin TA. Ocular bobbing in encephalitis. Journal Neurology Neurosurg Psychiat 1981;44:441-443.
  3. Rudick RA. Intracerebral hematoma as an incidental finding. Archives Neurology 1981;38:396.
  4. Rudick RA, Scott DE, Herndon RM. Murine ventriculosubarachnoid space morphology. Brain Res Bull 1981;7:509-515.
  5. Schiffer R, Rudick RA, Herndon RM. Emotional aspects of MS. New York State Medical Journal 1981;83:312-316.
  6. McCusker EA, Rudick RA, Honch G, Griggs RC. Recovery from locked-in syndrome. Archives Neurology 1982;39:145-147.
  7. Rudick RA, Zirretta DK, Herndon RM. Clearance of albumin from mouse subarachnoid space: A measure of CSF bulk flow. Journal Neuroscience Methods 1982;6:253-260.
  8. Rudick RA, Eskin RA. Neuropathologic features of a lupus-like disorder in auto-immune mice. Annals Neurology 1983;14:325-332.
  9. Rudick RA, Buell SJ. Integrity of blood-brain barrier to peroxidase in senescent mice. Neurobiol Aging 1983;4:283-287.
  10. Rudick RA, Bloechl EK, Knutson DW. Preparation of monoclonal antibody-ferritin conjugates of high specific activity. Histochemistry 1984;80:269-272.
  11. Knutson DW, Rudick RA, Herndon RM. Isolation of model soluble immune complexes in the fluid phase by monoclonal anti-IgG-ferritin antibodies. Scandinavian Journal Immunology 1985;21:1-9.
  12. Rudick RA. Humoral immunity in multiple sclerosis: Clinical and investigative aspects. Seminars Neurology 1985;5:107-116.
  13. Rudick RA, Peter DM, Bidlack JM, Knutson DW. Multiple sclerosis: Free light chains in cerebrospinal fluid. Neurology 1985;35:1443-1449.
  14. Rudick RA, Bidlack JM, Knutson DW. Multiple sclerosis: Immune complexes in CSF that bind Clq. Archives Neurology 1985;42:856-858.
  15. Schiffer RB, Rudick RA, Herndon RM. Pathological laughing and weeping: Treatment with amitriptyline. New England Journal Medicine 1986;312:1480-1482.
  16. French CA, Tracy RP, Rudick RA, Kraemer A, Arvan DA. The simultaneous determination of cerebrospinal fluid oligoclonal bands and gamma-protein index by agarose electrophoresis and densitometry. Clinical Chemistry, 1986;32:84-87.
  17. Rudick RA, Pallant A, Bidlack JM, Herndon RM. Free kappa chains in multiple sclerosis spinal fluid. Annals Neurology 1986;20:63-69.
  18. Mehta RL, Takahashi H, Rudick RA, Knutson DW. Binding and catabolism of aggregated immunoglobulins containing C3b by U937 cells. Journal Immunology, 1986;136:1-7.
  19. Rudick RA, Jacobs LD, Kinkel P, Kinkel WR. Analysis of free kappa light chains in CSF of patients with isolated idiopathic optic neuritis. Correlation with nuclear magnetic resonance findings. Archives Neurology, 1986;43:452-455.
  20. Rudick RA, Schiffer RB, Schwetz K, Herndon RM. Multiple sclerosis: The problem of misdiagnosis. Archives Neurology, 1986;43:578-584.
  21. Simon JH, Holtas S, Schiffer RB, Rudick RA, Herndon RM, Kido DK, Utz R. Corpus callosum and subcallosal-periventricular lesions in multiple sclerosis: Detection with MR. Radiology, 1986;160:363-367.
  22. Birk K, Rudick RA. Pregnancy and multiple sclerosis. Archives Neurology, 1986;43:719-726.
  23. Rudick RA, Schiffer RB, Herndon RM. Drug Treatment of multiple sclerosis. Seminars Neurology, 1987;7:150-159.
  24. DeCarli C, Menegus M, Rudick RA. Free light chains in multiple sclerosis and CNS infections. Neurology, 1987;37:1334-1338.
  25. Rudick RA, Breton D, Krall RL. The GABA-agonist progabide for spasticity in multiple sclerosis. Archives Neurology, 1987;44:1033-1036.
  26. Simon JH, Schiffer RB, Rudick RA, Herndon RM. Quantitative determination of MS-induced corpus callosum atrophy in vivo using MR imaging. American Journal Neuroradiology, 1987;8:559-604.
  27. Rudick RA, Whitaker JN. Cerebrospinal fluid tests for multiple sclerosis. Neurology and Neurosurgery Update Series, 1987;7:1-8.
  28. Birk K, Smeltzer S, Rudick RA. Pregnancy in Multiple Sclerosis. Seminars Neurology, 1988;8:205-213.
  29. Smeltzer SC, Utell MJ, Rudick RA, Herndon RM. Pulmonary function and dysfunction in multiple sclerosis. Archives Neurology, 1988;45:1245-1249.
  30. Rudick RA, French CA, Breton D, Williams GW. Relative diagnostic value of cerebrospinal fluid kappa chains in multiple sclerosis. Comparison with other immunoglobulin tests. Neurology, 1989;39:964-968.
  31. Estes ML, Rudick RA, Huang TE, Rorick M, Rosenbloom SA. A 29-year-old renal transplant patient with multiple brain lesions. Cleveland Clinic Journal of Medicine, 1989;56:304-310.
  32. Smith AS, Meisler DM, Weinstein MA, Tomsak RL, Hanson MR, Rudick RA, et al. High-signal periventricular lesions in patients with sarcoidosis: Neurosarcoidosis or multiple sclerosis?. American Journal Neuroradiology, 1989;10:485-490.
  33. Birk KA, Rudick RA. Caring for the obstetric patient with multiple sclerosis, Contemporary Ob/Gyn, 1989;34:58-72.
  34. Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospectively followed MS population: Implications for clinical trials. Archives Neurology, 1989;46:1107-1112.
  35. Birk KA, Ford C, Smeltzer S, Ryan D, Miller R, Rudick RA. The clinical course of multiple sclerosis during pregnancy and the puerperium. Archives Neurology, 1990;47:738-742.
  36. Estes ML, Rudick RA, Barnett GH, Ransohoff RM. Stereotactic biopsy of an active multiple sclerosis lesion: Immunocytochemical analysis and neuropathologic correlation with magnetic resonance imaging. Archives Neurology, 1990;47:1299-1303.
  37. Rudick RA. Helping patients live with multiple sclerosis: What primary care physicians can do. Postgraduate Medicine, 1990;88:197-207.
  38. Stanescu GL, Swick AR, Tuohy VK, Rudick RA. Sensitive competitive-binding ELISAS for quantifying free kappa and lambda light chains in cerebral spinal fluid. Journal of Clinical Laboratory Analysis, 1991;5:206-211.
  39. Goodkin DE, Doolittle TH, Hauser SS, Ransohoff RM, Roses AD, Rudick RA. Diagnostic criteria for multiple sclerosis in multiply affected families. Archives Neurology, 1991;48:805-807.
  40. Ransohoff RM, Devajyothi C, Estes ML, Babcock G, Rudick RA, et al. Interferon-beta specifically inhibits interferon-gamma-induced class II major histocompatibility complex gene transcription in human astrocytes. Journal of Neuroimmunology, 1991;33:103-112.
  41. Whiting DM, Barnett GH, Estes ML, Sila CA, Rudick RA, Hassenbusch SJ, Lanzieri F. Stereotactic biopsy of non-neoplastic lesions in adults. Cleveland Clinic Journal of Medicine, 1992;59:48-55.
  42. Goodkin DE, Ransohoff RM, Rudick RA. Treatment of multiple sclerosis: Current status. Part 1. Clinical trials of experimental therapies in MS. Cleveland Clinic Journal of Medicine, 1992;59:63-74.
  43. Goodkin DE, Ross J, Medendorp SV, Konecsni J, Rudick RA. MRI lesions englargement in multiple sclerosis: Disease-related activity, chance occurrence, or measurement artifact? Archives Neurology, 1992;49:261-263.
  44. Rudick RA, Ransohoff RM. Cytokine secretion by multiple sclerosis monocytes: Relationship to disease activity. Archives Neurology, 1992;49:265-270.
  45. Rudick RA, Goodkin DE, Ransohoff RM. Treatment of multiple sclerosis: Current status. Part 2. Symptom pharmacotherapy. Cleveland Clinic Journal of Medicine, 1992;59:267-277.
  46. Shah M, Ross JS, VanDyke C, Rudick R, Goodkin D, Obuchowski N, Modic MT. Volume T1 weighted gradient echo MR imaging in multiple sclerosis patients, Journal Computer Assisted Tomography, 1992;16;731-736.
  47. Ransohoff RM, Tuohy VK, Barna BP, Rudick RA. Monocytes in active multiple sclerosis: Intact regulation of HLA-DR density in vitro despite decreased HLA-DR density in vivo. Journal Neuroimmunology 1992;37:169-176.
  48. Goodkin DE, Rudick RA, Vanderbrug Medendorp S, Greene T, et al. Low-dose (7.5mg) oral methotrexate for chronic progressive multiple sclerosis: Design of a randomized placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data of toxicity. Online Journal Current Clinical Trials [serial online] 1992;Sep 25 (Doc No 19).
  49. Rudick RA, Miller DM, Clough JD, Gragg LA, Farmer RG. Quality of life in multiple sclerosis. Archives Neurology 1992;49:1237-1242.
  50. Rudick RA, Carpenter CS, Cookfair DL, Tuohy VK, Ransohoff RM. In vitro and in vivo inhibition of mitogen-driven T cell activation by recombinant interferon beta. Neurology 1993;43:2080-2087.
  51. Goodkin DE, Rudick RA, Ross JS. The use of brain magnetic resonance imaging in multiple sclerosis. Archives Neurology 1994;51:505-516.
  52. Jacobs L, Goodkin DE, Rudick RA, Herndon R. Advances in specific therapy to modify the course of multiple sclerosis. Current Opinion in Neurology 1994;7:250-254.
  53. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: Biologic effects, mechanisms of action, and use in multiple sclerosis. Annals Neurology, 1995;37:7-15.
  54. Goodkin DE, Rudick RA, Medendorp SV, Daughtry MM, Schwetz KM, Fischer J, Van Dyke C. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Annals Neurology 1995;37:30-40.
  55. Rudick RA, Ransohoff RM. Biological effects of interferons: Relevance to multiple sclerosis. Multiple Sclerosis. 1995;1:S12-S17.
  56. Rudick RA, Medendorp S, Namey M, Boyle S, Fischer J. Multiple sclerosis progression in a natural history study: Predictive value of cerebrospinal fluid free kappa light chains. Multiple Sclerosis, 1995;1:150-155.
  57. Jacobs LD, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular recombinant beta interferon as treatment for exacerbating-remitting multiple sclerosis: Design and conduct of study and baseline characteristics of patients. Multiple Sclerosis, 1995;1:118-135.
  58. Rolak LA, Beck RW, Paty DW, Tourtellotte WW, Whitaker JN, Rudick RA, and the Optic Neuritis Study Group. Cerebrospinal fluid in acute optic neuritis: Experience of the optic neuritis treatment trial. Neurology, 1996;46:368-372.
  59. Wineman NM, Schwetz KM, Goodkin DE, Rudick RA. Relationships among illness uncertainty, stress, coping, and emotional well-being at entry into a clinical drug trial. Applied Nursing Research, 1996;9:53-60.
  60. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Annals of Neurology, 1996;39:285-294.
  61. Rudick, R., Antel, J., Confavreux, C., Cutter, G., Ellison, G., Fischer, J., Lublin, F., Miller, A., Petkau, J., Rao, S., Reingold, S., Syndulko, K., Thompson, A., Wallenberg, J., Weinshenker, B., and Willoughby, E. Clinical outcomes assessment in multiple sclerosis. Annals of Neurology 1996;40:469-479.
  62. Goodkin, D.E., Rudick, R.A., Medendorp, S.V., Daughtry, M.M., and Van Dyke, C. Low-dose oral methotrexate in chronic progressive multiple sclerosis: Analyses of serial MRI scans. Neurology 1996;47:1153-1157.
  63. Rudick RA, Ransohoff RM, Peppler R, VanderBrug Medendorp S, LehmAnnals P, Alam, J. Interferon beta induces interleukin-10 expression: Relevance to multiple sclerosis. Annals Neurology, 1996;40:618-627.
  64. Weinstock-Guttman B, Kinkel RP, Cohen JA, Ransohoff RM, Schwetz K, Gogol D, Namey M, Rudick RA. Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. The Neurologist, 1997;3:178-185.
  65. Mohr DC, Goodkin DE, Likosky W, Gatto N, BaumAnnals KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Archives of Neurology, 1997;54:531-533.
  66. Weinstock-Guttman B, Rudick RA. Prescribing recommendations for interferon-beta in multiple sclerosis. CNS Drugs, 1997;8:102-112.
  67. Rudick RA, Goodkin DE, Jacobs LD, et al. The impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997;49:358-363.
  68. Rudick RA , Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby, E. Recommendations from the clinical outcomes assessment task force of the National Multiple Sclerosis Society. Annals of Neurology, 1997;42:379-382.
  69. Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Management of multiple sclerosis. New England Journal of Medicine, 1997;337:1604-1611.
  70. Kinkel RP, Rudick RA, Ransohoff RM. Rapid neurological deterioration in a patient with multiple sclerosis treated with systemic interleukin-2 and interferon-alpha 2b for metastatic renal cell carcinoma. Journal Neurology Neurosurgery Psychiatry, 1997;62:100.
  71. Rudick RA. The ten most common questions about the management of multiple sclerosis. The Neurologist, 1997;3:367-371.
  72. Aikens JE, Fischer JS, Namey M, Rudick RA. A replicated prospective investigation of life stress, coping, and depressive symptoms in multiple sclerosis. Journal Behavioral Medicine 1997;20:433-445.
  73. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Annals Neurology. 1998;43:79-87.
  74. Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FE, Cookfair DL, Simon JH, Jacobs LD, and the MSCRG. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology, 1998;50:1266-1273.
  75. Rudick RA, Ransohoff RM, Lee Jar-Chi S, Peppler R, Yu M, Mathesin P, Tuohy VK. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998;50:1294-1301.
  76. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transections in the lesions of multiple sclerosis. New England Journal of Medicine, 1998;338:278?285.
  77. Goodkin DE, Priore RL, Wende KE, Campion M, Bourdette DN, Herndon RM, Fischer JS, Jacobs LD, Cookfair DL, Rudick RA, et al. Comparing the ability of various composite outcomes to discriminate treatment effects in MS clinical trials. Multiple Sclerosis 1998;4:480-486.
  78. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to eurologic disability. Curr Opin Neurol. 1999;12:295-302.
  79. Rudick RA.Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics. Arch Neurol. 1999;56:1079-84.
  80. Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, et al. Cerebrospinal Fluid Abnormalities In A Phase III Trial Of Avonex (IFNß?1a) For Relapsing Multiple Sclerosis. Journal Neuroimmunology, 1999;93:8-14.
  81. Rudick RA.A 29-year-old man with multiple sclerosis. Journal of the American Medical Association. 1999;280:1432-1439.
  82. Trapp BD, Ransohoff RM, Fisher E, Rudick RA. Neurodegeneration in multiple sclerosis: Relationship to neurological disability. The Neuroscientist, 1999;5:48-57.
  83. Zemlan FP, Rosenberg WS, Luebbe PA, Campbell TA, Dean GE, Weiner NE, Cohen JA, Rudick RA, Woo D. Quantification of axonal damage in traumatic brain injury: Affinity purification and characterization of cerebrospinal fluid tau proteins. Journal of Neurochemistry. 1999;72:741-750.
  84. Rudick RA, Goodman A, Herndon RM, Panitch HS. Selecting relapsing remitting MS patients for treatment: The case for early treatment. Journal Neuroimmunology, 1999, 98:22-28.
  85. Cutter GR, Baier ML, Rudick RA. Development of the Multiple Sclerosis Functional Composite as an Outcome Measure for Clinical Trials. Brain, 1999;122:871-882.
  86. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The multiple sclerosis functional composite measure (MSFC): An integrated approach to MS clinical outcome assessment. Multiple Sclerosis 1999,5:244-250.
  87. Simon JH, Jacobs L, Campion M, Rudick R, et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 1999;53:139-148.
  88. Rudick RA. The Case For Early Diagnosis And Treatment In Relapsing Remitting Multiple Sclerosis. International Journal of MS Care. 1999;1:6-20.
  89. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L, and the MSCRG. Use of the brain parenchymal fraction to monitor whole brain atrophy in relapsing remitting multiple sclerosis. Neurology, 1999;53:1698-1704.
  90. Herndon RM, Jacobs LD, Coats ME, Goodkin DE, Mass MK, Richert JR, Rudick RA, Waubant EL, Weinstock-Guttman B, Scaramucci JO, Burnett BK, Jones WE, Simonian NA. Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis. International Journal of MS Care 1999;2:1-6.
  91. Simon JH, Lull J, Jacobs LD, Rudick RA, Cookfair DL, et al. A longitudinal study of T1- hypointense lesions (T1- black holes) in relapsing multiple sclerosis: Natural history and treatment outcome results from the MS collaborative research group trial of interferon beta-1a. Neurology, 2000;55:185-192.
  92. Jacobs L, Rudick R, Simon J. Extended observations on MS patients treated with IM interferon beta-1a (Avonex): Implications for modern MS trials and therapeutics. Journal Neuroimmunology. 2000;107:167-174.
  93. Pelfrey CM, Rudick RA, Cotleur AC, Lee J-C, Lehmann MT, Lehmann PV. Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. Journal Immunology, 2000;165:1641-1651.
  94. Rudick RA, Fisher E. The effect of interferon beta on brain atrophy. Multiple Sclerosis Quarterly 2000;19:6-9.
  95. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol. 2000;48:893-901.
  96. Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Ann Neurol. 2000;48:885-92.
  97. Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS. Clinical significance of the multiple sclerosis functional composite: Relationship to patient-reported quality of life. Arch Neurol. 2000;57:1319-24.
  98. Miller DM, Weinstock-Guttman B, Bethoux F, Lee JC, Beck G, Block V, Durelli L, LaMantia L, Barnes D, Sellebjerg F, Rudick RA. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler. 2000;6:267-73.
  99. Jacobs L, Rudick R, Simon J. Extended observations on MS patients treated with IM interferon-beta1a (Avonex): Implications for modern MS trials and therapeutics. J Neuroimmunol. 2000;107:167-73.
  100. Rudick RA. How does one define progression of disease in patients with relapsing-remitting multiple sclerosis? Arch Neurol. 2000;57:425-6.
  101. Liu Z, Pelfrey CM, Cotleur A, Lee J, Rudick RA. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol. 2001;112:153-62.
  102. Waubant E, Gee L, Bacchetti P, Sloan R, Cotleur A, Rudick R, Goodkin D. Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS. J Neuroimmunol. 2001;112:139-45.
  103. Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B, Mass K, Miller D, Simonian NA. How well does the multiple sclerosis functional composite predict neurological outcome in relapsing-remitting multiple sclerosis? Annals of Neurology 2001;50:70. 93.
  104. Moldovan IR, Cotleur B, Lee J-C, Rudick RA, Pelfrey CM. Longitudinal cytokine responses to myelin peptides: correlation with clinical parameters in multiple sclerosis (MS). J Neuroimmunol. 2001;118:136.
  105. Pelfrey CM, Moldovan IR, Cotleur AC, Lee J-C, Rudick RA. Quantification of longitudinal cytokine responses to myelin peptides in multiple sclerosis. Clinical Immunology 2001;99:131.
  106. Weinstock-Guttman B, Baier M, LeeKwen P, Feichter J, Dinehart S, Venkatraman J, Meksawan K, Rensel M, Bochiechio P, Brownscheidle C, Munschauer F, Rudick RA. A randomized study of low-fat diet w-3 fatty acid supplementation in patients with relapsing -remitting multiple sclerosis (RRMS). Neurology 2002;58:A461.
  107. Bakshi R, Puli SR, Tjoa CW, Bermel RA, Fisher E, Rudick RA, et al. Gray matter T2 hypointensity in multiple sclerosis: a 2-year longitudinal clinical-MRI study of 79 patients. Neurology 2002;58:A154. 98. Moldovan IR, Born S, Cotleur AC, Karafa M, Lee J-C, Fisher E, Rudick RA, Pelfrey CM. Cytokine responses to myelin peptides correlate with clinical parameters in multiple sclerosis. Neurology 2002;58:A70.
  108. Moldovan IR, Born SE, Cotleur AC, Karafa M, Lee J-C, Fisher E, Rudick RA, Pelfrey CM. Cytokine responses to myelin peptides: correlation with clinical parameters in multiple sclerosis. FASEB Journal 2002;16:A1061.
  109. Pelfrey CM, Moldovan IR, Born S, Cotleur AC, Karafa M, Lee J-C, Fisher E, Rudick RA. Longitudinal cytokine responses to myelin peptides in multiple sclerosis: persistence and spreading of immune responses. Neurology 2002;58:A70.
  110. Pelfrey CM, Moldovan IR, Born SE, Cotleur AC, Karafa M, Lee J-C, Fisher E, Rudick RA. Longitudinal cytokine responses to myelin peptides in multiple sclerosis (MS): persistence and spreading of immune responses. FASEB Journal 2002;16:A1062.
  111. Radue EW, Kappos L, Simonian N, Kooijmans M, Clanet M, Slasor P, Rudick RA. MRI results of the European interferon beta-1a dose-comparison study. Neurology 2002;58:A204. 103. Hardmeier M, Freitag P, Wagenpfeil S, Fisher E, Rudick RA. Detectable atrophy occurs within three months in relapsing-remitting MS (RRMS). Neurology 2002;58:A503.
  112. Rudick RA, Cutter G, Baier M, Dougherty D, Weinstock-Guttman B, Mass M, et al. Gadolinium enhancing lesions as a surrogate marker of interferon response. Multiple Sclerosis 2002;66:S21.
  113. Trapp BD, Bjartmar C, Peterson J, Chang A, Rudick RA. Inflammation, Demyelination and Axonal Loss: Insights from Pathology. Multiple Sclerosis 2002;8:S4-S5.
  114. Pelfrey CM, Moldovan IR, Cotleur AC, Born SE, Karafa M, Lee J, Fisher E, Rudick RA. Longitudinal cytokine responses to myelin peptides in MS: persistence and spreading of immune responses. Multiple Sclerosis 2002:8:S52.
  115. Weinstock-Guttman B, Baier M, Feichter J, Gallagher E, Vekatraman J, Meksawan K, Youngmin P, Rudick RA. A randomized study of low fat diet with ?-3 fatty acid supplementation in patients with relapsing-remitting multiple sclerosis. Neurology 2003, in press.
  116. Rudick RA, Fisher E, Lee JC. Annual rate of whole brain atrophy in multiple sclerosis: comparison with healthy controls. Neurology 2003;60:A421 (Suppl 1).
  117. Rudick RA, Sandrock A, Panzara M, Polman C. Study designs of two phase III trials to determine the safety and efficacy of Natalizumab (antegren®) alone and when added to interferon beta 1a (Avonex®) in patients with relapsing-remitting multiple sclerosis. Neurology 2003;60:A479 (Suppl 1).
  118. Moldovan IR, Rudick RA, Cotleur AC, Born SE, Lee JC, Karafa MT, Fisher E, Pelfrey Multiple sclerosis-associated HLA-DR alleles contribute to persistence of myelin responses in MS patients. Neurology 2003;60:A266 (Suppl 1).
  119. Baier ML, Golden CO, Rudick RA, Cutter GR. Evaluation of a vision test for contrast letter acuity for inclusion in the multiple sclerosis functional composite. Neurology 2003;60:A56 (Suppl 1).
  120. Hardmeier M, Wagenpfeil S, Fisher E, Rudick RA, Kooijmans M, Clanet M, Radue EW, Kappos L. Predictors of atrophy during treatment with rIFN-beta 1a IM in relapsing multiple sclerosis: A three year follow-up. Neurology 2003;60:A300 (Suppl 1).
  121. Bermel RA, Puli SR, Fabiano AJ, Fisher E, Rudick RA, Weinstock-Guttman B, Simon JH, Munschauer FE, Bakshi R. Gray matter MRI T2 hypointensity predicts longitudinal brain atrophy in multiple sclerosis: Effect of intramuscular interferon beta-1a treatment. Neurology 2003;60:S51-003, A422 (Suppl 1).

back to top